Preliminary Clinical Data from Ongoing Phase 1b/2a Clinical Program Presented at New Directions in Biology and Disease of Skeletal Muscle 6th Biennial Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...

CAMBRIDGE, Mass., Jul 03, 2014 (BUSINESS WIRE) -- Akashi Therapeutics, Inc. , announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's most ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy (DMD), today reported that ...

The HT-100 is an all-terrain, day/night, adverse-weather-capable unmanned helicopter UAE-based defence-tech group Edge held a capability demonstration for the ANAVIA HT-100 unmanned helicopter within ...

With the HT-100, ANAVIA has developed the most advanced unmanned aerial vehicle (UAV) system in the world. An unmanned helicopter for up to 65 kg of payload and 240 minutes of flight time. It’s the ...

EDGE’s Swiss subsidiary Anavia has demonstrated what its parent company describes as a “complex flight profile” with an HT-100 unmanned air vehicle for the Brazilian armed forces and police. Recently ...

Halo Therapeutics announced that the FDA has granted orphan drug designation for HT-100 (halofuginone) for Duchenne muscular dystrophy (DMD). Plans to initiate a Phase 2 trial in 2012 are underway.

Dubai, United Arab Emirates: EDGE Group entity, Abu Dhabi Ship Building (ADSB), has adopted several HT-100 multi-role unmanned performance helicopters for integration onto the vessels of one of its ...